SI-BONE: Q2 Earnings Insights
SI-BONE (NASDAQ:SIBN) reported its Q2 earnings results on Monday, August 8, 2022 at 04:00 PM.
Here's what investors need to know about the announcement.
SI-BONE’s Earnings: A Preview
SI-BONE (NASDAQ:SIBN) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement.
Analysts estimate that SI-BONE will report an earnings per share (EPS) of $-0.49.
Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $18
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $22 to $18.
SI-BONE, Inc. Receives FDA 510(k) Clearance For iFuse Bedrock Granite, A Breakthrough Pelvic Fixation And Fusion Technology
SI-BONE, Inc., (NASDAQ:SIBN), a Silicon Valley-based medical device company dedicated to solving musculoskeletal disorders of the sacropelvic anatomy, announces FDA 510(k) premarket clearance of the iFuse Bedrock
Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $22
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $28 to $22.
Earnings Scheduled For May 9, 2022
Companies Reporting Before The Bell
• Atlantica Sustainable (NASDAQ:AY) is likely to report quarterly loss at $0.08 per share on revenue of $277.90 million.
SI-BONE’s Earnings Outlook
SI-BONE (NASDAQ:SIBN) is set to give its latest quarterly earnings report on Monday, 2022-05-09. Here's what investors need to know before the announcement.
Analysts estimate that SI-BONE will report an earnings per share (EPS) of $-0.43.
Morgan Stanley Maintains Overweight on SI-BONE, Lowers Price Target to $28
Morgan Stanley analyst Drew Ranieri maintains SI-BONE (NASDAQ:SIBN) with a Overweight and lowers the price target from $30 to $28.
Earnings Scheduled For February 28, 2022
Companies Reporting Before The Bell
• Lexicon Pharmaceuticals (NASDAQ:LXRX) is estimated to report earnings for its fourth quarter.
